Hearing scheduled for Scripps Park sidewalk widening A city of San Diego hearing officer is scheduled to consider plans to ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...

A single signaling pathway controls whether immune cells attack or befriend cells they encounter while patrolling our bodies, researchers at Stanford ...

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement - OBT's second high-profile pharma ...

The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...

BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the ...

This paper aims to critique the argument constructed by Anna Smajdor and Joona Räsänen that pregnancy is a disease. Their argument that pregnancy fits the features of disease they enumerate stems from ...

Zentalis has taken a beating in 2025 to date, as the market continues to value their pipeline as a liability rather than an ...

Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with ...

Amid NIH funding delays, reversals and uncertainty, a scientist at Harvard who studies breast cancer has lost one-third of ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for ...